spacer
spacer

PDBsum entry 1l3e

Go to PDB code: 
protein metals Protein-protein interface(s) links
Transcription PDB id
1l3e

 

 

 

 

Loading ...

 
JSmol PyMol  
Contents
Protein chains
42 a.a. *
101 a.a. *
Metals
_ZN ×3
* Residue conservation analysis
PDB id:
1l3e
Name: Transcription
Title: Nmr structures of the hif-1alpha ctad/p300 ch1 complex
Structure: Hypoxia inducible factor-1 alpha subunit. Chain: a. Fragment: c-terminal transactivation domain (ctad). Engineered: yes. P300 protein. Chain: b. Fragment: cysteine/histidine-rich 1 domain (ch1). Engineered: yes
Source: Homo sapiens. Human. Organism_taxid: 9606. Gene: hypoxia inducible factor-1 alpha. Expressed in: escherichia coli bl21. Expression_system_taxid: 511693. Gene: p300.
NMR struc: 17 models
Authors: S.J.Freedman,Z.J.Sun,F.Poy,A.L.Kung,D.M.Livingston,G.Wagner,M.J.Eck
Key ref:
S.J.Freedman et al. (2002). Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 alpha. Proc Natl Acad Sci U S A, 99, 5367-5372. PubMed id: 11959990 DOI: 10.1073/pnas.082117899
Date:
26-Feb-02     Release date:   24-Apr-02    
PROCHECK
Go to PROCHECK summary
 Headers
 References

Protein chain
Pfam   ArchSchema ?
Q16665  (HIF1A_HUMAN) -  Hypoxia-inducible factor 1-alpha from Homo sapiens
Seq:
Struc:
 
Seq:
Struc:
826 a.a.
42 a.a.*
Protein chain
Pfam   ArchSchema ?
Q09472  (EP300_HUMAN) -  Histone acetyltransferase p300 from Homo sapiens
Seq:
Struc:
 
Seq:
Struc:
 
Seq:
Struc:
 
Seq:
Struc:
 
Seq:
Struc:
2414 a.a.
101 a.a.
Key:    PfamA domain  Secondary structure  CATH domain
* PDB and UniProt seqs differ at 1 residue position (black cross)

 Enzyme reactions 
   Enzyme class 1: Chain B: E.C.2.3.1.-  - ?????
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
   Enzyme class 2: Chain B: E.C.2.3.1.48  - histone acetyltransferase.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction: L-lysyl-[protein] + acetyl-CoA = N6-acetyl-L-lysyl-[protein] + CoA + H+
L-lysyl-[protein]
+ acetyl-CoA
= N(6)-acetyl-L-lysyl-[protein]
+ CoA
+ H(+)
Note, where more than one E.C. class is given (as above), each may correspond to a different protein domain or, in the case of polyprotein precursors, to a different mature protein.
Molecule diagrams generated from .mol files obtained from the KEGG ftp site

 

 
    Added reference    
 
 
DOI no: 10.1073/pnas.082117899 Proc Natl Acad Sci U S A 99:5367-5372 (2002)
PubMed id: 11959990  
 
 
Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 alpha.
S.J.Freedman, Z.Y.Sun, F.Poy, A.L.Kung, D.M.Livingston, G.Wagner, M.J.Eck.
 
  ABSTRACT  
 
Adaptation to hypoxia is mediated by transactivation of hypoxia-responsive genes by hypoxia-inducible factor-1 (HIF-1) in complex with the CBP and p300 transcriptional coactivators. We report the solution structure of the cysteine/histidine-rich 1 (CH1) domain of p300 bound to the C-terminal transactivation domain of HIF-1 alpha. CH1 has a triangular geometry composed of four alpha-helices with three intervening Zn(2+)-coordinating centers. CH1 serves as a scaffold for folding of the HIF-1 alpha C-terminal transactivation domain, which forms a vise-like clamp on the CH1 domain that is stabilized by extensive hydrophobic and polar interactions. The structure reveals the mechanism of specific recognition of p300 by HIF-1 alpha, and shows how HIF-1 alpha transactivation is regulated by asparagine hydroxylation.
 
  Selected figure(s)  
 
Figure 1.
Fig. 1. Domain structures and sequence alignments of HIF-1 and p300 and structure of the CTAD/CH1 complex. (a) Functional domains of CBP/p300 (Upper) and HIF-1 (Lower). Domains in CBP/p300 are nuclear hormone receptor-binding domain (Nu), cysteine/histidine-rich domains (CH1, CH2, and CH3), CREB-binding domain (KIX), bromodomain (Br), histone acetyltransferase domain (HAT), glutamine-rich domain (Q), and IRF-3-binding domain (I). The CH1 and CH3 domains are structurally homologous and also have been termed TAZ1 and TAZ2, respectively. Domains in HIF-1 are basic helix-loop-helix domain (bHLH), Per-Arnt-Sim homology domain (PAS), and N- and C-terminal transactivation domains (NTAD, CTAD). Transcription factors that have been shown to associate with CBP/p300 are shown above the interacting domains. Those that have been structurally characterized in complex with their respective CBP/p300 binding domains are highlighted in red. The domains of p300 and HIF-1 that form the complex studied here are highlighted in dark blue and red, respectively. This figure was adapted from Vo and Goodman, 2001 (16). (b) The sequence of the human HIF-1 CTAD used for structure determination (top line) is aligned with the homologous regions of HIF-1 from other species and human HIF-2 . Note that the structured portion of HIF-1 (residues 792-824) is nearly 100% conserved. (b and c) Elements of secondary structure are indicated above the alignment. The shaded vertical bars above the alignment indicate the fraction of the residue surface that is buried in the HIF-1 /p300 complex interface. (c) The sequence of human p300 CH1 used for structure determination (top line) is aligned with the homologous regions of p300 and CBP. The single histidine and three cysteines that form each of the three strictly conserved Zn2+-binding sites are shaded violet, green, or yellow. Residues highlighted in blue are conserved residues that form the hydrophobic core of the human CH1 structure. Most of these residues are conserved in the CH3 domain. The residues that are buried in the interface between the HIF-1 CTAD and p300 CH1 domain are distributed among all four helices but are most prominent along 3. The arrowheads under the alignment indicate the positions of insertions relative to the human p300 CH1 sequence. The number of residues inserted in the CH3 domains are indicated; those numbers with asterisks are insertions in the C. elegans sequence of CBP CH1. The aligned sequences are: h, Homo sapiens; b, Bos taurus; m, Mus musculus; x, Xenopus laevis; d, Drosophila melanogaster; c, Caenorhabditis elegans. (d) Stereoview of 17 superimposed CTAD/CH1 complex structures. (e) Ribbon diagram of the lowest-energy CTAD/CH1 structure. The fold of CH1 (royal blue/light blue) and CTAD (red/orange) is described in the text. Helices 1 (residues 332-354), 2 (residues 367-379), 3 (residues 391-405), and 4 (residues 414-418) refer to the -helical regions of p300 CH1; residues 332-334 are 3:10 helix. Helices A (residues 797-803) and B (residues 816-822) refer to the -helical regions of the HIF-1 CTAD; residues 815-817 are 3:10 helix. Green spheres indicate the three putative Zn2+ ions in CH1 and are labeled Zn1 through Zn3. (f) Superposition of the CH1 domain from the CTAD/CH1 complex with the free CBP CH3 domain (25). Note the similar folds from 1 through 3 (gray) and the conformational differences of the third Zn2+-binding turn and 4 (CH1 residues 407-418 in blue and CH3 residues 1835-1850 in yellow). The eight-residue insertion (residues 353-363) in the first Zn2+-binding turn of CH1 relative to the homologous region of CH3 (residues 1788-1790) is similarly color-coded. d was prepared with MOLMOL (40), e was prepared with MOLSCRIPT (41), and f was prepared with INSIGHTII (Accelrys).
Figure 2.
Fig. 2. Intermolecular contacts between the HIF-1 CTAD and p300 CH1 domains. (a) A region of the CTAD/CH1 complex is magnified to illustrate some of the important hydrophobic contacts that define the topology of the interaction. CTAD wraps around CH1 like a clamp such that A and B rest in grooves on either side of 3. Note the parallel configuration of the CH1 helix sandwiched between the two CTAD helices. Several hydrophobic side chains considered to contribute to the binding energy are displayed as sticks and are labeled by residue and number. (b) A similar region of the complex (interhelical loop of CTAD, N terminus of 1 and 3 from CH1) is shown in a different orientation to illustrate putative intermolecular hydrogen bond contacts that stabilize the complex. The presence of hydrogen bonds is supported by NOE and structure analyses. (c and d) The N- and C-terminal regions of the HIF-1 CTAD (red ribbon) are shown with the p300 CH1 domain represented as an accessible surface. The surface is colored by charge and is scaled from 10 kT/e (red) to +10 kT/e (blue). Selected HIF-1 side chains are labeled in black. Basic residues in CH1 are labeled in white. (e) Position of Asn-803 in the CTAD/CH1 complex indicates how -hydroxylation would inhibit binding. CH1 residues are shown in yellow and CTAD residues are shown in white. The Asn-803 H (pro-R) and H (pro-S) are colored green. Van der Waals surfaces are shown for residues surrounding the Asn-803 side chain. Substitution of either the pro-R or pro-S -protons with a hydroxyl group would disfavor complex formation because of steric and hydrogen-bonding considerations (see text). (a, b, and e) Complexes were prepared with INSIGHTII (Accelrys). (c and d) Complexes were prepared with GRASP (42).
 
  Figures were selected by the author.  

Literature references that cite this PDB file's key reference

  PubMed id Reference
21386837 M.N.Khan, T.Bhattacharyya, P.Andrikopoulos, M.A.Esteban, R.Barod, T.Connor, M.Ashcroft, P.H.Maxwell, and S.Kiriakidis (2011).
Factor inhibiting HIF (FIH-1) promotes renal cancer cell survival by protecting cells from HIF-1α-mediated apoptosis.
  Br J Cancer, 104, 1151-1159.  
21316481 S.H.Li, Y.S.Chun, J.H.Lim, L.E.Huang, and J.W.Park (2011).
von Hippel-Lindau protein adjusts oxygen sensing of the FIH asparaginyl hydroxylase.
  Int J Biochem Cell Biol, 43, 795-804.  
20882602 S.Kushal, H.Wang, C.F.László, L.Z.Szábo, and B.Z.Olenyuk (2011).
Inhibition of hypoxia-inducible transcription factor complex with designed epipolythiodiketopiperazine.
  Biopolymers, 95, 8.  
19880525 J.L.Ruas, U.Berchner-Pfannschmidt, S.Malik, K.Gradin, J.Fandrey, R.G.Roeder, T.Pereira, and L.Poellinger (2010).
Complex regulation of the transactivation function of hypoxia-inducible factor-1 alpha by direct interaction with two distinct domains of the CREB-binding protein/p300.
  J Biol Chem, 285, 2601-2609.  
19926662 K.G.Pringle, K.L.Kind, A.N.Sferruzzi-Perri, J.G.Thompson, and C.T.Roberts (2010).
Beyond oxygen: complex regulation and activity of hypoxia inducible factors in pregnancy.
  Hum Reprod Update, 16, 415-431.  
20821791 L.K.Henchey, J.R.Porter, I.Ghosh, and P.S.Arora (2010).
High specificity in protein recognition by hydrogen-bond-surrogate α-helices: selective inhibition of the p53/MDM2 complex.
  Chembiochem, 11, 2104-2107.  
20147748 L.W.Lee, and A.K.Mapp (2010).
Transcriptional switches: chemical approaches to gene regulation.
  J Biol Chem, 285, 11033-11038.  
20616042 M.Kjaergaard, K.Teilum, and F.M.Poulsen (2010).
Conformational selection in the molten globule state of the nuclear coactivator binding domain of CBP.
  Proc Natl Acad Sci U S A, 107, 12535-12540.
PDB code: 2kkj
20569445 M.Koda, L.Kanczuga-Koda, M.Sulkowska, E.Surmacz, and S.Sulkowski (2010).
Relationships between hypoxia markers and the leptin system, estrogen receptors in human primary and metastatic breast cancer: effects of preoperative chemotherapy.
  BMC Cancer, 10, 320.  
20534573 M.L.Nelson, H.S.Kang, G.M.Lee, A.G.Blaszczak, D.K.Lau, L.P.McIntosh, and B.J.Graves (2010).
Ras signaling requires dynamic properties of Ets1 for phosphorylation-enhanced binding to coactivator CBP.
  Proc Natl Acad Sci U S A, 107, 10026-10031.
PDB code: 2kmd
19755960 Y.Guan, K.R.Reddy, Q.Zhu, Y.Li, K.Lee, P.Weerasinghe, J.Prchal, G.L.Semenza, and N.Jing (2010).
G-rich oligonucleotides inhibit HIF-1alpha and HIF-2alpha and block tumor growth.
  Mol Ther, 18, 188-197.  
19680224 C.Huang, Y.Han, Y.Wang, X.Sun, S.Yan, E.T.Yeh, Y.Chen, H.Cang, H.Li, G.Shi, J.Cheng, X.Tang, and J.Yi (2009).
SENP3 is responsible for HIF-1 transactivation under mild oxidative stress via p300 de-SUMOylation.
  EMBO J, 28, 2748-2762.  
19805293 D.Shi, M.S.Pop, R.Kulikov, I.M.Love, A.L.Kung, A.Kung, and S.R.Grossman (2009).
CBP and p300 are cytoplasmic E4 polyubiquitin ligases for p53.
  Proc Natl Acad Sci U S A, 106, 16275-16280.  
19268693 E.Roudier, and A.Perrin (2009).
Considering the role of pyruvate in tumor cells during hypoxia.
  Biochim Biophys Acta, 1796, 55-62.  
19950993 J.Key, T.H.Scheuermann, P.C.Anderson, V.Daggett, and K.H.Gardner (2009).
Principles of ligand binding within a completely buried cavity in HIF2alpha PAS-B.
  J Am Chem Soc, 131, 17647-17654.
PDB codes: 3h7w 3h82
19214187 J.M.Wojciak, M.A.Martinez-Yamout, H.J.Dyson, and P.E.Wright (2009).
Structural basis for recruitment of CBP/p300 coactivators by STAT1 and STAT2 transactivation domains.
  EMBO J, 28, 948-958.
PDB codes: 2ka4 2ka6
  20975915 J.Upadhyay, R.K.Kesharwani, and K.Misra (2009).
Comparative study of antioxidants as cancer preventives through inhibition of HIF-1 alpha activity.
  Bioinformation, 4, 233-236.  
20000859 K.M.Block, H.Wang, L.Z.Szabó, N.W.Polaske, L.K.Henchey, R.Dubey, S.Kushal, C.F.László, J.Makhoul, Z.Song, E.J.Meuillet, and B.Z.Olenyuk (2009).
Direct inhibition of hypoxia-inducible transcription factor complex with designed dimeric epidithiodiketopiperazine.
  J Am Chem Soc, 131, 18078-18088.  
19589782 K.M.Cook, S.T.Hilton, J.Mecinovic, W.B.Motherwell, W.D.Figg, and C.J.Schofield (2009).
Epidithiodiketopiperazines block the interaction between hypoxia-inducible factor-1alpha (HIF-1alpha) and p300 by a zinc ejection mechanism.
  J Biol Chem, 284, 26831-26838.  
19081931 L.Kelly, M.A.McDonough, M.L.Coleman, P.J.Ratcliffe, and C.J.Schofield (2009).
Asparagine beta-hydroxylation stabilizes the ankyrin repeat domain fold.
  Mol Biosyst, 5, 52-58.
PDB codes: 2zgd 2zgg
19845602 M.E.Cockman, J.D.Webb, and P.J.Ratcliffe (2009).
FIH-dependent asparaginyl hydroxylation of ankyrin repeat domain-containing proteins.
  Ann N Y Acad Sci, 1177, 9.  
19519454 M.Miller (2009).
The importance of being flexible: the case of basic region leucine zipper transcriptional regulators.
  Curr Protein Pept Sci, 10, 244-269.  
19401150 S.E.Wilkins, J.Hyvärinen, J.Chicher, J.J.Gorman, D.J.Peet, R.L.Bilton, and P.Koivunen (2009).
Differences in hydroxylation and binding of Notch and HIF-1alpha demonstrate substrate selectivity for factor inhibiting HIF-1 (FIH-1).
  Int J Biochem Cell Biol, 41, 1563-1571.  
19402914 S.Fukuchi, K.Homma, Y.Minezaki, T.Gojobori, and K.Nishikawa (2009).
Development of an accurate classification system of proteins into structured and unstructured regions that uncovers novel structural domains: its application to human transcription factors.
  BMC Struct Biol, 9, 26.  
18842833 W.Feng, F.Ye, W.Xue, Z.Zhou, and Y.J.Kang (2009).
Copper regulation of hypoxia-inducible factor-1 activity.
  Mol Pharmacol, 75, 174-182.  
19186072 Z.K.Otrock, H.A.Hatoum, A.H.Awada, R.S.Ishak, and A.I.Shamseddine (2009).
Hypoxia-inducible factor in cancer angiogenesis: structure, regulation and clinical perspectives.
  Crit Rev Oncol Hematol, 70, 93.  
18404207 A.G.Turjanski, J.S.Gutkind, R.B.Best, and G.Hummer (2008).
Binding-induced folding of a natively unstructured transcription factor.
  PLoS Comput Biol, 4, e1000060.  
18375543 A.J.Filiano, C.D.Bailey, J.Tucholski, S.Gundemir, and G.V.Johnson (2008).
Transglutaminase 2 protects against ischemic insult, interacts with HIF1beta, and attenuates HIF1 signaling.
  FASEB J, 22, 2662-2675.  
18538455 F.S.Lee (2008).
Genetic causes of erythrocytosis and the oxygen-sensing pathway.
  Blood Rev, 22, 321-332.  
18574470 G.Xenaki, T.Ontikatze, R.Rajendran, I.J.Stratford, C.Dive, M.Krstic-Demonacos, and C.Demonacos (2008).
PCAF is an HIF-1alpha cofactor that regulates p53 transcriptional activity in hypoxia.
  Oncogene, 27, 5785-5796.  
18295234 H.S.Kang, M.L.Nelson, C.D.Mackereth, M.Schärpf, B.J.Graves, and L.P.McIntosh (2008).
Identification and structural characterization of a CBP/p300-binding domain from the ETS family transcription factor GABP alpha.
  J Mol Biol, 377, 636-646.
PDB code: 2juo
18202699 K.Lisy, and D.J.Peet (2008).
Turn me on: regulating HIF transcriptional activity.
  Cell Death Differ, 15, 642-649.  
17970581 K.Salnikow, and A.Zhitkovich (2008).
Genetic and epigenetic mechanisms in metal carcinogenesis and cocarcinogenesis: nickel, arsenic, and chromium.
  Chem Res Toxicol, 21, 28-44.  
18568157 R.Chowdhury, A.Hardy, and C.J.Schofield (2008).
The human oxygen sensing machinery and its manipulation.
  Chem Soc Rev, 37, 1308-1319.  
18059036 S.Kaluz, M.Kaluzová, and E.J.Stanbridge (2008).
Does inhibition of degradation of hypoxia-inducible factor (HIF) alpha always lead to activation of HIF? Lessons learnt from the effect of proteasomal inhibition on HIF activity.
  J Cell Biochem, 104, 536-544.  
18505681 S.Kaluz, M.Kaluzová, and E.J.Stanbridge (2008).
Regulation of gene expression by hypoxia: integration of the HIF-transduced hypoxic signal at the hypoxia-responsive element.
  Clin Chim Acta, 395, 6.  
18219320 T.Klimova, and N.S.Chandel (2008).
Mitochondrial complex III regulates hypoxic activation of HIF.
  Cell Death Differ, 15, 660-666.  
18830487 Y.H.Chen, L.M.Comeaux, S.J.Eyles, and M.J.Knapp (2008).
Auto-hydroxylation of FIH-1: an Fe(ii), alpha-ketoglutarate-dependent human hypoxia sensor.
  Chem Commun (Camb), (), 4768-4770.  
18458062 Y.Li, T.Kimura, R.W.Huyck, J.H.Laity, and G.K.Andrews (2008).
Zinc-induced formation of a coactivator complex containing the zinc-sensing transcription factor MTF-1, p300/CBP, and Sp1.
  Mol Cell Biol, 28, 4275-4284.  
17292925 A.B.Johnson, and M.C.Barton (2007).
Hypoxia-induced and stress-specific changes in chromatin structure and function.
  Mutat Res, 618, 149-162.  
17301803 A.Ozer, and R.K.Bruick (2007).
Non-heme dioxygenases: cellular sensors and regulators jelly rolled into one?
  Nat Chem Biol, 3, 144-153.  
17438265 D.P.Teufel, S.M.Freund, M.Bycroft, and A.R.Fersht (2007).
Four domains of p300 each bind tightly to a sequence spanning both transactivation subdomains of p53.
  Proc Natl Acad Sci U S A, 104, 7009-7014.  
17562787 E.L.Bell, T.A.Klimova, J.Eisenbart, C.T.Moraes, M.P.Murphy, G.R.Budinger, and N.S.Chandel (2007).
The Qo site of the mitochondrial complex III is required for the transduction of hypoxic signaling via reactive oxygen species production.
  J Cell Biol, 177, 1029-1036.  
17682059 J.Li, E.Wang, S.Dutta, J.S.Lau, S.W.Jiang, K.Datta, and D.Mukhopadhyay (2007).
Protein kinase C-mediated modulation of FIH-1 expression by the homeodomain protein CDP/Cut/Cux.
  Mol Cell Biol, 27, 7345-7353.  
17935336 K.Sugase, J.C.Lansing, H.J.Dyson, and P.E.Wright (2007).
Tailoring relaxation dispersion experiments for fast-associating protein complexes.
  J Am Chem Soc, 129, 13406-13407.  
17220275 Q.Yan, S.Bartz, M.Mao, L.Li, and W.G.Kaelin (2007).
The hypoxia-inducible factor 2alpha N-terminal and C-terminal transactivation domains cooperate to promote renal tumorigenesis in vivo.
  Mol Cell Biol, 27, 2092-2102.  
17081102 A.Huwiler, and J.Pfeilschifter (2006).
Hypoxia and lipid signaling.
  Biol Chem, 387, 1321-1328.  
16412252 C.Hebert, K.Norris, P.Parashar, R.A.Ord, N.G.Nikitakis, and J.J.Sauk (2006).
Hypoxia-inducible factor-1alpha polymorphisms and TSC1/2 mutations are complementary in head and neck cancers.
  Mol Cancer, 5, 3.  
16170363 C.J.Anderson, S.F.Hoare, M.Ashcroft, A.E.Bilsland, and W.N.Keith (2006).
Hypoxic regulation of telomerase gene expression by transcriptional and post-transcriptional mechanisms.
  Oncogene, 25, 61-69.  
16842166 D.G.Nagle, and Y.D.Zhou (2006).
Natural product-derived small molecule activators of hypoxia-inducible factor-1 (HIF-1).
  Curr Pharm Des, 12, 2673-2688.  
16635809 D.Jung, Y.Choi, and M.Uesugi (2006).
Small organic molecules that modulate gene transcription.
  Drug Discov Today, 11, 452-457.  
16543236 D.M.Fath, X.Kong, D.Liang, Z.Lin, A.Chou, Y.Jiang, J.Fang, J.Caro, and N.Sang (2006).
Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha.
  J Biol Chem, 281, 13612-13619.  
16548775 G.L.Semenza (2006).
Development of novel therapeutic strategies that target HIF-1.
  Expert Opin Ther Targets, 10, 267-280.  
16925945 M.Ohh (2006).
Ubiquitin pathway in VHL cancer syndrome.
  Neoplasia, 8, 623-629.  
16847340 S.Kaluz, M.Kaluzová, and E.J.Stanbridge (2006).
Proteasomal inhibition attenuates transcriptional activity of hypoxia-inducible factor 1 (HIF-1) via specific effect on the HIF-1alpha C-terminal activation domain.
  Mol Cell Biol, 26, 5895-5907.  
  17003483 Z.Khan, G.K.Michalopoulos, and D.B.Stolz (2006).
Peroxisomal localization of hypoxia-inducible factors and hypoxia-inducible factor regulatory hydroxylases in primary rat hepatocytes exposed to hypoxia-reoxygenation.
  Am J Pathol, 169, 1251-1269.  
16389310 D.E.Merry (2005).
Animal models of Kennedy disease.
  NeuroRx, 2, 471-479.  
15738986 H.J.Dyson, and P.E.Wright (2005).
Intrinsically unstructured proteins and their functions.
  Nat Rev Mol Cell Biol, 6, 197-208.  
15908239 J.L.Ruas, and L.Poellinger (2005).
Hypoxia-dependent activation of HIF into a transcriptional regulator.
  Semin Cell Dev Biol, 16, 514-522.  
  15866766 K.Salnikow, and K.S.Kasprzak (2005).
Ascorbate depletion: a critical step in nickel carcinogenesis?
  Environ Health Perspect, 113, 577-584.  
16237459 L.H.Kasper, F.Boussouar, K.Boyd, W.Xu, M.Biesen, J.Rehg, T.A.Baudino, J.L.Cleveland, and P.K.Brindle (2005).
Two transactivation mechanisms cooperate for the bulk of HIF-1-responsive gene expression.
  EMBO J, 24, 3846-3858.  
15629713 N.Sánchez-Puig, D.B.Veprintsev, and A.R.Fersht (2005).
Binding of natively unfolded HIF-1alpha ODD domain to p53.
  Mol Cell, 17, 11-21.  
15800008 T.Gaber, R.Dziurla, R.Tripmacher, G.R.Burmester, and F.Buttgereit (2005).
Hypoxia inducible factor (HIF) in rheumatology: low O2! See what HIF can do!
  Ann Rheum Dis, 64, 971-980.  
15952883 W.G.Kaelin (2005).
Proline hydroxylation and gene expression.
  Annu Rev Biochem, 74, 115-128.  
15563310 B.K.McColl, S.A.Stacker, and M.G.Achen (2004).
Molecular regulation of the VEGF family -- inducers of angiogenesis and lymphangiogenesis.
  APMIS, 112, 463-480.  
15003169 B.L.Sopher, P.S.Thomas, M.A.LaFevre-Bernt, I.E.Holm, S.A.Wilke, C.B.Ware, L.W.Jin, R.T.Libby, L.M.Ellerby, and A.R.La Spada (2004).
Androgen receptor YAC transgenic mice recapitulate SBMA motor neuronopathy and implicate VEGF164 in the motor neuron degeneration.
  Neuron, 41, 687-699.  
15122348 C.J.Schofield, and P.J.Ratcliffe (2004).
Oxygen sensing by HIF hydroxylases.
  Nat Rev Mol Cell Biol, 5, 343-354.  
15152194 F.R.Sharp, and M.Bernaudin (2004).
HIF1 and oxygen sensing in the brain.
  Nat Rev Neurosci, 5, 437-448.  
15717005 F.R.Sharp, R.Ran, A.Lu, Y.Tang, K.I.Strauss, T.Glass, T.Ardizzone, and M.Bernaudin (2004).
Hypoxic preconditioning protects against ischemic brain injury.
  NeuroRx, 1, 26-35.  
15030454 H.Kiyosawa, T.Kawashima, D.Silva, N.Petrovsky, Y.Hasegawa, K.Sakai, and Y.Hayashizaki (2004).
Systematic genome-wide approach to positional candidate cloning for identification of novel human disease genes.
  Intern Med J, 34, 79-90.  
15341784 K.S.Hewitson, and C.J.Schofield (2004).
The HIF pathway as a therapeutic target.
  Drug Discov Today, 9, 704-711.  
15071503 M.Koshiji, Y.Kageyama, E.A.Pete, I.Horikawa, J.C.Barrett, and L.E.Huang (2004).
HIF-1alpha induces cell cycle arrest by functionally counteracting Myc.
  EMBO J, 23, 1949-1956.  
12732728 B.D.Nguyen, K.L.Abbott, K.Potempa, M.S.Kobor, J.Archambault, J.Greenblatt, P.Legault, and J.G.Omichinski (2003).
NMR structure of a complex containing the TFIIF subunit RAP74 and the RNA polymerase II carboxyl-terminal domain phosphatase FCP1.
  Proc Natl Acad Sci U S A, 100, 5688-5693.
PDB code: 1onv
12603311 D.Lando, J.J.Gorman, M.L.Whitelaw, and D.J.Peet (2003).
Oxygen-dependent regulation of hypoxia-inducible factors by prolyl and asparaginyl hydroxylation.
  Eur J Biochem, 270, 781-790.  
13130303 G.L.Semenza (2003).
Targeting HIF-1 for cancer therapy.
  Nat Rev Cancer, 3, 721-732.  
  12639980 M.Safran, and W.G.Kaelin (2003).
HIF hydroxylation and the mammalian oxygen-sensing pathway.
  J Clin Invest, 111, 779-783.  
14668441 P.J.Erbel, P.B.Card, O.Karakuzu, R.K.Bruick, and K.H.Gardner (2003).
Structural basis for PAS domain heterodimerization in the basic helix--loop--helix-PAS transcription factor hypoxia-inducible factor.
  Proc Natl Acad Sci U S A, 100, 15504-15509.
PDB code: 1p97
12825087 S.Bhattacharya, and P.J.Ratcliffe (2003).
ExCITED about HIF.
  Nat Struct Biol, 10, 501-503.  
12778114 S.J.Freedman, Z.Y.Sun, A.L.Kung, D.S.France, G.Wagner, and M.J.Eck (2003).
Structural basis for negative regulation of hypoxia-inducible factor-1alpha by CITED2.
  Nat Struct Biol, 10, 504-512.
PDB code: 1p4q
12573436 W.Kim, and W.G.Kaelin (2003).
The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer.
  Curr Opin Genet Dev, 13, 55-60.  
12502741 C.Lee, J.H.Chang, H.S.Lee, and Y.Cho (2002).
Structural basis for the recognition of the E2F transactivation domain by the retinoblastoma tumor suppressor.
  Genes Dev, 16, 3199-3212.
PDB code: 1n4m
12186981 G.L.Semenza (2002).
Physiology meets biophysics: visualizing the interaction of hypoxia-inducible factor 1 alpha with p300 and CBP.
  Proc Natl Acad Sci U S A, 99, 11570-11572.  
12209156 W.G.Kaelin (2002).
Molecular basis of the VHL hereditary cancer syndrome.
  Nat Rev Cancer, 2, 673-682.  
The most recent references are shown first. Citation data come partly from CiteXplore and partly from an automated harvesting procedure. Note that this is likely to be only a partial list as not all journals are covered by either method. However, we are continually building up the citation data so more and more references will be included with time. Where a reference describes a PDB structure, the PDB code is shown on the right.

 

spacer

spacer